Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HEMHealing is an oxygenating hydrogel dressing developed by HEMARINA for the treatment of chronic and acute wounds, including deep burns. The product incorporates M101, a high-capacity extracellular hemoglobin derived from the marine lugworm *Arenicola marina*. Unlike human hemoglobin, M101 is a large, biopolymer molecule that can carry 40 times more oxygen and release it according to a partial pressure gradient. When applied topically, HEMHealing delivers oxygen directly to the hypoxic wound bed, promoting cellular proliferation, collagen synthesis, and overall tissue repair while providing anti-inflammatory and antibacterial benefits. It is currently classified as a medical device/biotech product in development and has been used under compassionate use authorization for full-thickness burns.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on HEMHealing.